The Crosstalk Mechanism of EGFR and ER in EGFR-Mutant Lung Adenocarcinoma.

Ying-Yi Chen, Wei-Ting Huang, Yu-Fu Su, Yi-Jen Hung, Hao-Ai Shui, Yi-Shing Shieh, Tsai-Wang Huang

Abstract read

In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Significant improvement in overall survival with postoperative traditional Chinese medicine in stage I lung adenocarcinoma: a real-world retrospective cohort study.Translational lung cancer research · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ying-Yi ChenGraduate Institute of Medical Sciences, College of Medicine, National Defense Medical University, Taipei 114202, Taiwan.ORCID 0000-0003-3753-4877

Wei-Ting HuangDepartment of Dentistry, Tri-Service General Hospital, National Defense Medical University, Taipei 114202, Taiwan.

Yu-Fu SuGraduate Institute of Medical Sciences, College of Medicine, National Defense Medical University, Taipei 114202, Taiwan.ORCID 0009-0003-6704-5270

Yi-Jen HungGraduate Institute of Medical Sciences, College of Medicine, National Defense Medical University, Taipei 114202, Taiwan.

Hao-Ai ShuiGraduate Institute of Medical Sciences, College of Medicine, National Defense Medical University, Taipei 114202, Taiwan.

Yi-Shing ShiehGraduate Institute of Medical Sciences, College of Medicine, National Defense Medical University, Taipei 114202, Taiwan.

Tsai-Wang HuangGraduate Institute of Medical Sciences, College of Medicine, National Defense Medical University, Taipei 114202, Taiwan.ORCID 0000-0001-8741-9223

Funding

medical civic action program of Medical Research Development Fund, Tri-Service General Hospital, National Defense Medical University. TSGH-C03-114036, TSGH-C03-114037, TSGH-C03-114038, TSGH-D-114112

6 · The paper itself

Abstract

Breast cancer and lung adenocarcinoma share common features, including female predominance and the expression of estrogen receptor (ER) and epidermal growth factor receptor (EGFR) during carcinogenesis. Patients with breast cancer have a significantly higher risk of developing second primary lung cancer than those without breast cancer. ER beta expression is associated with resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung adenocarcinoma, indicating a potentially important interaction between ER and EGFR. However, the mechanisms underlying this crosstalk remain poorly understood. Our clinical data showed a significant correlation between antiestrogen treatment for breast cancer and mutant EGFR expression (

Indexed as

Adenocarcinoma of LungLung NeoplasmsMutationReceptors, EstrogenCell Line, TumorErbB ReceptorsFemaleGefitinibHumansPhosphorylationProtein Kinase InhibitorsTamoxifenEGFR protein, humanErbB ReceptorsGefitinibProtein Kinase InhibitorsReceptors, EstrogenTamoxifenbreast cancerepidermal growth factor receptorestrogen receptorlung adenocarcinoma

Identifiers

PMID41597172

DOI10.3390/cells15020098

PMCPMC12838910

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.